Logo yposkesi
waves image
Your CDMO partner of choice for viral vector manufacturing

Latest News
Yposkesi’s virtual tour

Partnering to bring your Cell and Gene therapies to life...

Yposkesi building

Growing Capacity

Time is of essence in clinical development of new therapies, and manufacturing is often a real bottleneck for gene therapy products.  At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Our growing cGMP facilities, dedicated manpower and expertise allow us to easily  accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments.

Learn more about us
Yposkesi services

One-stop-shop

Yposkesi is a one-stop-shop with both technical expertise and a long-term commitment to quality.
Our services encompass process development, cGMP  manufacturing of AAV and lentiviral vectors, Fill&Finish, QC, QA and regulatory support. We aim to establish an open and trustworthy relationship with you with the ultimate goal  reducing time-to-market and ensuring an uninterrupted supply of viral vectors.

Discover what’s possible
Gene therapy Innovation

Innovation

There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products.
As a leading Contract Development Manufacturing Organization (CDMO), Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable and competitive AAV and lentiviral vector supplier.

Find out how we innovate

Who we are

Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing.

A one-stop shop for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 sq ft. (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substance (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 sq ft. (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance.

Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high quality gene-modified cell therapies and in vivo gene therapy projects.

Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

Bioprocess development (USP & DSP)

We use innovation to reach new heights in production efficiency.

Discover

GMP manufacturing of clinical and commercial viral vector batches

Our extensive AAV and lentiviral vector manufacturing capacity helps ensure on-time deliver.

Learn more

Analytical development, assays qualification & validation

Our experts aim to satisfy all your analytical needs with high quality.

Discover

Fill & Finish

We offer two options for Fill&Finish: Crystal® Closed Vial Technology or glass vials.

Learn more

Regulatory support

We provide strategic, technical and regulatory support.

Discover

Would you like to know more?

Contact us